Hua Medicine (Shanghai) Ltd.（02552.HK）股價、圖表、新聞與AI分析

Q: Hua Medicine (Shanghai) Ltd. 的 CEO 是誰？

Dr. Li Chen 是 Hua Medicine (Shanghai) Ltd. 的 Chief Executive Officer，自 2010 加入公司。

Q: HUA MEDICINE-B 股票的價格表現如何？

HUA MEDICINE-B 的當前價格為 $3.25，在上個交易日 下降 了 4.69%。

Q: Hua Medicine (Shanghai) Ltd. 的主要業務主題或行業是什麼？

Hua Medicine (Shanghai) Ltd. 屬於 Pharmaceuticals 行業，該板塊是 Health Care

Q: Hua Medicine (Shanghai) Ltd. 的市值是多少？

Hua Medicine (Shanghai) Ltd. 的當前市值是 $3.2B

首頁

股票

02552.HK

HUA MEDICINE-B (02552.HK)

Hua Medicine (Shanghai) Ltd.

HK$3.25

-4.69%

$-0.16

休市： Jan 16, 16:00:00 HKT

關鍵數據

前收市價

$3.41

開盤價

$3.41

當日範圍

$3.2 - $3.41

52週區間

$1.24 - $4.95

交易量

5.3M

平均成交量

3.5M

每股盈餘 (TTM)

1.21

股息收益率

市值

$3.2B

什麼是 HUA MEDICINE-B？

Hua Medicine Ltd. provides drug discovery and development services. The company is headquartered in Shanghai, Shanghai and currently employs 285 full-time employees. The company went IPO on 2018-09-14. The firm is also engaged in the commercialization of HuaTangNing products. The Company’s main product pipeline dorzagliatin or HMS5552 is a glucokinase activator or GKA, designed to control the progressive degenerative nature of diabetes by restoring glucose homeostasis in Type 2 diabetes. The firm mainly conducts its business in the domestic market.

功能特性

交易策略